Close Menu

NEW YORK (GenomeWeb) – Gene editing firm Horizon Discovery and Rutgers University announced today that they have signed a partnership deal to commercialize a gene editing technology developed in the lab of Rutgers Robert Wood Johnson Medical School pharmacology associate professor Shengkan Jin.

The base editing platform — which modifies genes by creating single point mutations in DNA without making double-stranded breaks — has potential applications in the development of new cell therapies and will augment Horizon's research tools and services, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.